3rd Quarter - Termination
ARENTFOX SCHIFF LLP for KEMPHARM, INC.
Firm
Client
Income
$10,000
Expenses
—
Terminated
Jul 31, 2018
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
FDA regulation of opioid abuse deterrent formulations
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
Health Issues HCR
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse deterrent legislation H.R. 6 (SUPPORT for Patients and Communities Act), provisions relating to HHS study on abuse deterrent formulations access barriers under Medicare H.R. 5582 (Abuse Deterrent Access Act of 2018), all provisions Pharmaceutical anti-opioid prodrug regulatory bill
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| NORMAN FREDERICK LENT | — |
| SONJA NESBIT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.